Molecular Partners AG (MOLN.SW)
CHF 3.35
(1.83%)
CHF 3.35
(1.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -61.1 Million CHF | -152.4% |
| 2022 | 116.61 Million CHF | 283.88% |
| 2021 | -63.41 Million CHF | -8.73% |
| 2020 | -58.32 Million CHF | -59.1% |
| 2019 | -36.66 Million CHF | 2.0% |
| 2018 | -37.41 Million CHF | -44.75% |
| 2017 | -25.84 Million CHF | -32.63% |
| 2016 | -19.48 Million CHF | -778.5% |
| 2015 | -2.21 Million CHF | -220.5% |
| 2014 | 1.84 Million CHF | -74.13% |
| 2013 | 7.11 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -15.85 Million CHF | 4.75% |
| 2024 Q3 | -14.58 Million CHF | 8.68% |
| 2024 Q2 | -15.97 Million CHF | -0.74% |
| 2023 Q2 | -15.88 Million CHF | -5.27% |
| 2023 Q1 | -15.08 Million CHF | -0.89% |
| 2023 Q4 | -16.64 Million CHF | -23.42% |
| 2023 Q3 | -13.48 Million CHF | 15.07% |
| 2023 FY | -61.1 Million CHF | -152.4% |
| 2022 Q3 | -14.69 Million CHF | -133.43% |
| 2022 Q1 | 152.55 Million CHF | 1066.27% |
| 2022 FY | 116.61 Million CHF | 283.88% |
| 2022 Q4 | -14.95 Million CHF | -1.79% |
| 2022 Q2 | -6.29 Million CHF | -104.13% |
| 2021 Q1 | -18.53 Million CHF | 7.64% |
| 2021 Q2 | -16.26 Million CHF | 12.23% |
| 2021 FY | -63.41 Million CHF | -8.73% |
| 2021 Q4 | -15.78 Million CHF | -22.99% |
| 2021 Q3 | -12.83 Million CHF | 21.07% |
| 2020 Q2 | -10.87 Million CHF | 11.03% |
| 2020 Q3 | -15.17 Million CHF | -39.54% |
| 2020 FY | -58.32 Million CHF | -59.1% |
| 2020 Q1 | -12.22 Million CHF | -0.75% |
| 2020 Q4 | -20.06 Million CHF | -32.25% |
| 2019 Q2 | -6.2 Million CHF | 0.0% |
| 2019 FY | -36.66 Million CHF | 2.0% |
| 2019 Q4 | -12.12 Million CHF | 0.0% |
| 2019 Q3 | -12.12 Million CHF | -95.62% |
| 2019 Q1 | -6.2 Million CHF | 49.86% |
| 2018 Q4 | -12.36 Million CHF | 0.0% |
| 2018 FY | -37.41 Million CHF | -44.75% |
| 2018 Q1 | -6.33 Million CHF | -39.08% |
| 2018 Q2 | -6.33 Million CHF | 0.0% |
| 2018 Q3 | -12.36 Million CHF | -95.12% |
| 2017 Q3 | -4.55 Million CHF | 54.57% |
| 2017 FY | -25.84 Million CHF | -32.63% |
| 2017 Q4 | -4.55 Million CHF | 0.0% |
| 2017 Q2 | -10.03 Million CHF | -49.7% |
| 2017 Q1 | -6.7 Million CHF | -4.92% |
| 2016 Q3 | -4.6 Million CHF | 27.18% |
| 2016 Q4 | -6.38 Million CHF | -38.83% |
| 2016 FY | -19.48 Million CHF | -778.5% |
| 2016 Q1 | -2.2 Million CHF | -324.71% |
| 2016 Q2 | -6.31 Million CHF | -187.14% |
| 2015 Q3 | 2.2 Million CHF | 162.48% |
| 2015 Q2 | -3.52 Million CHF | -780.28% |
| 2015 FY | -2.21 Million CHF | -220.5% |
| 2015 Q1 | -400 Thousand CHF | 12.9% |
| 2015 Q4 | -518 Thousand CHF | -123.55% |
| 2014 Q4 | -459.24 Thousand CHF | -157.41% |
| 2014 Q3 | 800 Thousand CHF | 6.73% |
| 2014 Q2 | 749.57 Thousand CHF | -0.0% |
| 2014 Q1 | 749.57 Thousand CHF | 231.39% |
| 2014 FY | 1.84 Million CHF | -74.13% |
| 2013 Q2 | 1.78 Million CHF | 0.0% |
| 2013 FY | 7.11 Million CHF | 0.0% |
| 2013 Q1 | 1.78 Million CHF | 0.0% |
| 2013 Q4 | -570.47 Thousand CHF | -131.95% |
| 2013 Q3 | 1.78 Million CHF | 0.0% |
| 2012 Q4 | 1.78 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | -492.638% |
| BB Biotech AG | -29.92 Million CHF | -104.183% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 418.188% |
| Evolva Holding SA | -92.24 Million CHF | 33.755% |
| Idorsia Ltd | -543.05 Million CHF | 88.747% |
| Kuros Biosciences AG | -13.19 Million CHF | -363.22% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | 44.862% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 188.763% |